What Happened

TScan Therapeutics reported initial Cohort C data from the ALLOHA Phase 1 study of TSC-101, showing 11 of 14 patients achieved complete donor chimerism within ~3 weeks of first infusion. The company also confirmed a 90% manufacturing success rate with its commercial-ready process and plans to begin Phase 3 enrollment this month.

Who Is Affected

This impacts hematologic malignancy patients undergoing allo-HCT, particularly those at high risk of relapse. Oncologists, transplant centers, and payers following TCR-T therapies should note these results as TScan prepares for Phase 3.

Market Impact

• Reinforces TScan's position in TCR-T therapy development
• Validates commercial-ready manufacturing process
• Creates potential competitive pressure on other allo-HCT adjuvant therapies
• Sets stage for Phase 3 execution and potential commercialization

What to Watch

Monitor enrollment progress in the Phase 3 ALLOHA-2 study starting this month. The June 22 KOL event with Dr. Ran Reshef may provide additional clinical insights. Long-term relapse outcomes remain the key efficacy measure to validate TSC-101's potential.